The amyotrophic lateral sclerosis functional rating scale: Assessment of activities of daily living in patients with amyotrophic lateral sclerosis

Archives of Neurology

Volumn 53, Issue 2, 1996, Pages 141-147

  Cedarbaum, Jesse M ^a  

^a REGENERON PHARMACEUTICALS INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CILIARY NEUROTROPHIC FACTOR; RECOMBINANT CILIARY NEUROTROPHIC FACTOR;

ADULT; AGED; AMYOTROPHIC LATERAL SCLEROSIS; ARTICLE; CLINICAL TRIAL; DAILY LIFE ACTIVITY; DYNAMOMETRY; FEMALE; FORCED EXPIRATORY VOLUME; HUMAN; LUNG FUNCTION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MUSCLE STRENGTH; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RATING SCALE; RELIABILITY;

EID: 0001163277     PISSN: 00039942     EISSN: None     Source Type: Journal    
DOI: 10.1001/archneur.1996.00550020045014     Document Type: Article

References (16)

1. Williams DB, Windebank AJ. Motor neuron disease (amyotrophic lateral sclerosis). Mayo Clin Proc. 1991;66:54-82.
2. Gubbay SS, Kahana E, Zilber N, Cooper G, Pintov S, Leibowitz Y. Amyotrophic lateral sclerosis, a study of its presentation and prognosis J Neurol. 1985; 232:295-300.
3. Mulder DW, Howard FH. Patient resistance and prognosis in amyotrophic lateral sclerosis. Mayo Clin Proc. 1976;51:537-541
4. Brooks B, Sufit R, DePaul R, Tan Y, Saniak M, Robbins J. Design of clinical therapeutic trials in amyotrophic lateral sclerosis Adv Neurol 1991;56:521-546.
5. Pradas J, Finison L, Andres PL, Thornell B, Hollander D, Munsat TL. The natural history of amyotrophic lateral sclerosis and the use of natural history controls in therapeutic trials. Neurology. 1993,43:751-755.
6. Ringel SP, Murphy JR, Alderson MK, et al. The natural history of amyotrophic lateral sclerosis. Neurology. 1993;43.1316-1322.
7. Anderson, RT, Aaronson NK, Wilin D. Critical review of the international assessments of health-related quality of life. Qual Life Res. 1993;2.369-395.
8. Morris FH, Calanchini PR, Fallat RJ, Pantry S, Jewett B. The administration of guanidine in amyotrophic lateral sclerosis Neurology. 1974,34:721-728.
9. Appel V, Stewart SS, Smith G, Appel SH A rating scale for amyotrophic lateral sclerosis. description and preliminary experience. Ann Neurol. 1987;22:328-333.
10. Fahn S, Elton R Unified Parkinson's Disease Rating Scale. In: Fahn S, Marsden C, eds. Recent Developments in Parkinson's Disease. New York, NY Macmillan Publishing Co Inc; 1987 153-163.
11. Hillel AD, Miller RM, Yorkston K, McDonald E, Norris FH, Konikow N. Amyotrophic Lateral Sclerosis Severity Scale. Neuroepidemiology. 1989,8:142-150.
12. Schwab R, England A. Projection technique for evaluating surgery in Parkinson's disease. In: Gillingham J, Donaldson I, eds. Third Symposium on Parkinson's Disease. Edinburgh, Scotland: E & S Livingstone; 1969:152-157.
13. Karnofsky DA, Burchenal JH. The clinical evaluation of chemotherapeutic agents in cancer. In: Maclead CM, ed Evaluation of Chemotherapeutic Agents Irvingtonon-Hudson, NY Columbia University Press, 1947.
14. Andres PL, Hedlund, Finison L, et al. Quantitative motor assessment in amyotrophic lateral sclerosis. Neurology. 1986;36:937-941
15. Suen HK. Principles of Test Theories Hillsdale, NJ: Lawrence Erlbaum Associates Inc Publishers; 1990:236.
16. Thurstone LL. A method of scaling psychological and educational tests. J Educ Psychol 1925;16:433-451